Effects of 1 mA and 2 mA transcranial direct current stimulation on working memory performance in healthy participants.
Cognitive load
Stimulation intensity
Working memory
tDCS
Journal
Consciousness and cognition
ISSN: 1090-2376
Titre abrégé: Conscious Cogn
Pays: United States
ID NLM: 9303140
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
12
2019
revised:
18
05
2020
accepted:
22
05
2020
pubmed:
6
6
2020
medline:
24
7
2021
entrez:
6
6
2020
Statut:
ppublish
Résumé
Anodal transcranial current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC) has been shown to enhance working memory (WM) in neuropsychiatric patients. In healthy populations, however, tDCS obtains inconclusive results, mostly due to heterogeneous study and stimulation protocols. Here, we approached these issues by investigating effects of tDCS intensity on simultaneous WM performance with three cognitive loads by directly comparing findings of two double-blind, cross-over, sham-controlled experiments. TDCS was administrated to the left DLPFC at intensity of 1 mA (Experiment 1) or 2 mA (Experiment 2), while participants completed a verbal n-back paradigm (1-, 2-, 3-back). Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load. The present study suggests that cognitive load rather than tDCS intensity could be a decisive factor for effects on WM. Moreover, it emphasizes the need of thorough investigation on study parameters to develop more efficient stimulation protocols.
Identifiants
pubmed: 32502908
pii: S1053-8100(19)30481-7
doi: 10.1016/j.concog.2020.102959
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102959Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: I.P, A.W., B.H, C.P. and T.S. report no conflict of interest. W.S. received paid speakership by Mag&More. P.F. was honorary speaker for Janssen-Cilag, Astra-Zeneca, Eli Lilly, Bristol Myers- Squibb, Lundbeck, Pfizer, Bayer Vital, SmithKline Beecham, Wyeth, and Essex. During the last 5 years, but not presently, he was a member of the advisory boards of Janssen-Cilag, AstraZeneca, Eli Lilly, and Lundbeck. F.P. has received speaker’s honorarium from Mag&More GmbH and the neuroCare Group as well as support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc., Jerusalem, Israel. A.F. reports no conflicts of interests related to the content of the report. A.H. has received a paid speakership from Desitin, Otsuka, Janssen and Lundbeck. He was member of an advisory boards of Janssen, Otsuka, Lundbeck and Roche.